Stéphanie B.
- Country
- France
- Department
- Oncology
Research Overview
- Efficacy and Safety of Giredestrant vs. Fulvestrant with CDK4/6 Inhibitor in ER+ HER2- Advanced Breast Cancer Resistant to Endocrine Therapy
- Phase 3 Multicenter Randomized Study of Trastuzumab Deruxtecan vs. Trastuzumab Emtansine in High-Risk HER2-Positive Breast Cancer with Residual Disease
- Evaluation of Ocular Toxicity Mitigation with Mirvetuximab Soravtansine, Brimonidine Tartrate, and Prednisolone Acetate in Recurrent Ovarian Cancer Patients
Data & Insights
Has run more than one trial at 98 of 315 partner sites.
Specializations
Breast Cancer Research
Specializes in investigating advanced treatments for hormone receptor-positive (HR+) and HER2-positive/negative breast cancers, with particular focus on metastatic conditions.
- Advanced therapeutic approaches for HR+/HER2- breast cancer
- Novel treatments for high-risk HER2+ breast cancer
- Innovative combination therapies for metastatic breast cancer
Explores targeted therapies including immunotherapy combinations and antibody-drug conjugates for breast cancer treatment.
Ovarian Cancer Studies
Focuses on developing treatments for advanced ovarian cancer variants, including rare subtypes and platinum-resistant cases.
- Small cell ovarian carcinoma treatment protocols
- Folate receptor-alpha targeted therapies
- Advanced epithelial ovarian cancer treatments
Investigates personalized treatment approaches for various ovarian cancer subtypes with emphasis on chemotherapy optimization.
Precision Oncology
Specializes in biomarker-driven treatment approaches and the development of targeted therapeutic strategies.
- Receptor-targeted therapeutic development
- Chemotherapy optimization protocols
- Novel drug combination strategies
Conducts research on personalized treatment approaches based on specific molecular and genetic markers.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.